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Resumen
Objetivo: Describir la utilización del recambio plasmático terapéutico 
(RPT) en distintas patologías y su ajuste a las guías internacionales de 
referencia. 
Método: Estudio observacional, descriptivo y retrospectivo en pacien-
tes que recibieron plasmaféresis entre enero de 2014 y diciembre de 
2015. Se analizó la adecuación de su indicación según la bibliografía 
consultada, así como la respuesta obtenida. El Servicio de Hematología 
estableció la indicación, el volumen plasmático a recambiar, el número 
de sesiones y la periodicidad según la enfermedad de base y su evolu-
ción clínica. 
Resultados: Diez pacientes (8 mujeres) entre 28 y 72 años de edad, 
recibieron RPT. Las patologías eran de origen neurológico (9 pacientes), 
enfermedad de Waldenström (1 paciente). La técnica utilizada fue centri-
fugación continua con albúmina 5% como líquido de reposición. 
Conclusiones: El RPT en los pacientes revisados se ajustó a las guías 
de referencia. No se observó correlación directa entre el grado de re-
comendación establecido por dichas guías y la respuesta obtenida. El 
número reducido de pacientes supone una limitación a la hora de extraer 
resultados concluyentes. 
Abstract
Objective: To descrive the use of therapeutic plasma exchange in se-
veral pathologies and its adjustment to international reference guides. 
Method: Observational, descriptive, retrospective study, of all the pa-
tients that received plasmapheresis between January 2014-December 
2015. We analized the appropriate indication according to the biblio-
graphy consulted, and the therapeutic outcome. Indication, replaced 
volume of plasma, number of sessions and periodicity were established 
by the Hematology Service depending on the disease and its clinical 
course. 
Results: 10 patients (8 women), between 28-72 years old, received 
therapeutic plasma exchange. The pathologies treated were neurological 
(9 patients), Waldenström disease (1 patient). The technique used was 
continuous centrifugation with albumin 5% as replacement fluid. 
Conclusions: The therapeutic plasma exchange in reviewed patients 
agreed to reference guides. There was not a direct relation between the 
recommendation grade and the response obtained. The reduced number 
of patients is a limitation to obtain conclusive results.
KEY WORDS
Blood component removal; Plasma Exchange; Plasmapheresis; 
Neurological diseases; Hematological diseases; Albumin.
PALABRAS CLAVE
Recambio plasmático terapéutico; Intercambio de plasma; 
Plasmaféresis; Enfermedades neurológicas; Enfermedades 
hematológicas; Albúmina.
BRIEFS ORIGINALS
Bilingual edition english/spanish
Use of plasma exchange as therapeutic tool in 
clinical practice
Utilización del recambio plasmático como 
herramienta terapéutica en la práctica clínica
Isabel Laura Campano-Pérez, Rosario Olivera-Fernández, 
Lara González-Freire, Carlos Crespo-Diz
Servicio de Farmacia, Complejo Hospitalario Universitario de Pontevedra, Pontevedra. Spain.
Author of correspondence
Isabel Laura Campano-Pérez
Servicio de Farmacia, Complejo Hospitalario 
Universitario de Pontevedra, Mourente s/n, 
36071 Pontevedra. España.
Correo electrónico: 
isabel.laura.campano.perez@sergas.es
Recibido el 30 de junio de 2017; 
aceptado el 20 de septiembre de 2017.
DOI: 10.7399/fh.10845
004_10845 - Utilización del recambio_ING.indd   16 03/01/2018   13:12
17
Farmacia Hospi ta lar ia 2018
l Vol. 42 l Nº 1 l 16 - 19 lUse of plasma exchange as therapeutic tool in clinical practice
Introduction
Therapeutic Plasma Exchange (TPE) is an extracorporeal blood purifi-
cation technique, which consists in the extraction of a specific volume of 
plasma that is exchanged for a replacement fluid. The aim of this technique 
is to remove large-molecular-weight substances, pathogens, or immunocom-
plexes circulating in the plasma that intervene in the pathological immune 
response and that are considered responsible for a disease or its clinical 
manifestations. 
Although TPE has been used in more than 80 diseases, such as renal, 
metabolic, autoimmune, rheumatologic, haematologic, neurologic, digesti-
ve, and hepatic disease, there is relatively little experience worldwide with 
this technique. Because these diseases are uncommon, the use of TPE is 
supported by case series rather than by controlled studies, thus making it 
difficult to obtain a solid level of evidence. 
Currently, TPE plays an important role mainly in the treatment of autoim-
mune disease and is a valid option in the case of disease refractory to 
conventional treatment. However, depending on the indications, great va-
riations in outcomes have been observed in clinical practice. The American 
Society for Apheresis (ASFA) has published guidelines on the use of TPE. The 
guidelines establish 4 categories that are constantly reviewed and updated 
taking into account the data provided by published clinical research1.
The objective of this work was to describe the use of TPE in several 
pathologies and to determine adherence to accepted international guide-
lines.
Methods
An observational descriptive retrospective study which included all pa-
tients who received TPE from January 2014 to December 2015 in a public 
tertiary hospital. 
The ASFA guidelines were used to verify the appropriateness of the 
indications for TPE1,2. The Grading of Recommendations, Assessment, Deve-
lopment, and Evaluation (GRADE) system was also used. This system assigns 
grades of recommendation based on the quality of the published evidence 
(Table 1)3.
The IANUS® electronic clinical record platform was used to obtain the 
following variables: age, sex, pathology, number of TPEs received in 1 
year, replacement fluid used, duration of treatment, concomitant medication, 
adverse reactions, and response. All data were anonymised according to 
the procedure established by Law 41/2002 of November 14, 20024.
TPE was performed in the hospital blood bank using a Spectra Op-
tia Apheresis System® with continuous flow centrifugation through a central 
catheter. Acid-citrate-dextrose (ACD) was used as the anticoagulant. Oral 
calcium carbonate was administered before the procedure to prevent hy-
pocalcaemia. The extracted plasma volume (PV) was replaced with 5% 
albumin5.
The Haematology Service established indications, PV to be replaced, 
and the number and frequency of sessions in all patients based on the 
underlying disease and its clinical course.
The Pharmacy Service analysed the use of TPE for different pathologies 
by evaluating the appropriateness of indications using the criteria establis-
hed by the ASFA and the available literature.
Results
During the study period, TPE was ordered for 11 patients (8 women 
and 3 men) between 28 years and 72 years of age (median 46 years). 
Nine patients had pathologies of neurological origin (81.8% of patients), 
and 1 patient had Waldenström’s macroglobulinemia. However, TPE was 
not performed in 1 patient with acute hypertriglyceridemia associated with 
severe pancreatitis (monitored in Intensive Care and Endocrinology and 
Nutrition Services) due to its successful treatment with standard measures 
(fluid therapy, insulin, diet). 
In the group of 9 patients with neurological indications for different 
pathologies, TPE was used as first-line treatment in a patient with Guillain-
Barré syndrome and as an alternative after the failure of standard treatment 
in the other 8 patients. In the haematologic patient with Waldenström’s 
macroglobulinemia, TPE was used as a first-line treatment to reduce excess 
paraproteins prior to initiating specific treatment.
In all patients, a 5% human albumin solution equivalent to 1 to 1.5 PV 
was used as replacement fluid and adjusted according to patient tolerance. 
The mean replacement fluid volume was 1.27 PV. 
During the study period, only 3 of the 10 treated patients underwent 
more than 1 TPE procedure. There was a median of 6 sessions per TPE 
procedure (range 1-12 sessions). The duration of each session ranged from 
2 to 3 hours. 
Concomitant medications administered during TPE were cyclosporine 
(1 patient), gentamicin (1 patient), amikacin (4 patients), and vancomycin 
(2 patients). Antiepileptic agents (phenobarbital, phenytoin, and valproic 
acid) were administered to 1 patient after TPE. Pharmacokinetic monitoring 
was used to determine and adjust the plasma levels of these agents5.
In all patients, the haematologist administered prophylactic oral calcium 
carbonate for hypocalcaemia before TPE and intravenous calcium after TPE 
as needed. 
TPE was well tolerated in 70% of the patients, none of whom expe-
rienced adverse reactions. During the first session, 1 patient experienced 
nausea and vomiting, but subsequently showed improved tolerance to 
treatment. Two patients experienced central catheter-related infections.
Table 2 shows the characteristics of each patient. 
Discussion
In this case series, the most common pathologies were of neurological 
origin. However, the most favourable result was obtained in the haemato-
logic patient with Waldenström’s macroglobulinemia6-8 (patient K; category 
I, grade 1C)1 in whom hyperviscosity caused by high IgM-protein levels 
prevented the initiation of treatment. After a single first-line TPE session, 
treatment with bortezomib and corticosteroids could be initiated. Clinical 
and analytical stability was achieved, making it unnecessary to initiate 
treatment with rituximab as originally planned. Despite the complexity of 
the patient’s condition, TPE improved the result of the pharmacological 
treatment, thus avoiding the use of more complex and expensive therapeutic 
measures. The literature reports the use of TPE as a pre-treatment measure to 
reduce hyperviscosity due to high IgM levels, given that hyperviscosity and 
IgM levels can be reduced by 60% and by 50%, respectively8. 
Of the 2 neurological patients diagnosed with Guillain-Barré syndro-
me3,9, patient C received TPE as a first-line treatment (category I, grade 
Table 1. Grades of recommendation and category for TPE of the American Society for Apheresis (ASFA)3
Grades of recommendation Category
GRADE 1
Strong recommendation
GRADE 2
Weak recommendation I
TPE accepted as first-line therapy, either as a standalone 
treatment or in conjunction with other treatments
Grade A High-quality evidence based on randomized clinical trials without limitations II
TPE accepted as second-line therapy, either as a standalone 
treatment or in conjunction with other treatments
Grade B
Moderate-quality evidence based on 
randomized clinical trials with important 
limitations
III The role of TPE is not well established, decision-making should be individualized
Grade C Low- or very low-quality evidence based on observational studies or case series IV
TPE is ineffective and even harmful according to published 
evidence
TPE, Therapeutic plasma exchange. Extracted from: Laínez-Andrés JM et al. Recambio plasmático terapéutico: aplicaciones en Neurología. Rev Neurol. 2015;60(3):120-31
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1A)1. After failing to respond to initial treatment, patient B received TPE as a 
second-line treatment (category III, grade 2C)1, with poor outcome. Despite 
the high grade of recommendation for TPE in patient C, the patient did not 
respond as expected and had to be referred to the Rehabilitation Service. 
Patient B did not respond to TPE, and the subsequent course of the disease 
was torpid. 
Despite category III and grade 2C1 for TPE, a very favourable initial res-
ponse was obtained in the 2 patients (I and J) with voltage-gated potassium 
channel antibody-associated encephalitis10,11. Patient I was discharged with 
antiepileptic treatment without subsequent readmission, whereas in patient 
J, despite the good initial response to TPE, the course of the disease was 
torpid and further TPE procedures were performed after the study period. 
The patient died. In line with results reported in the literature11, the patients 
experienced a subjective temporary improvement that was associated with 
the TPE procedure.
Myasthenia gravis (category I, grade 1B)1 is a neurological indication for 
which TPE has been shown to be very effective. Patient A had generalized 
myasthenia gravis, seronegative, and refractory to treatment with immuno-
suppressants, intravenous immunoglobulins (IVIG), and steroids. TPE led to 
a partial improvement of symptoms. These results coincide with those of the 
published literature. A retrospective study by Kumar et al.12 in 35 patients 
with myasthenia gravis showed short-term improvements in myasthenic seizu-
res. Mandawat et al.13 compared TPE and IVIG for the treatment of myasthe-
nia gravis, and found that both treatments had clinically similar outcomes, 
Table 2. Summary of patient characteristics and outcomes after TPE.
Patients Age Sex Indication Service Course No. TPE in 1 year
ASFA 
recommendation
Treatment 
line Post-TPE outcome
A 28 M
Generalized 
myasthenia gravis, 
seronegative, 
resistant
Neurology
Refractory to 
immunosuppressants, 
IVIG, and 
corticosteroids
5 Category I, grade 1B 2nd
Partial response
Good tolerance
B 69 F
Guillain-Barré 
syndrome
with flaccid 
tetraparesis and 
areflexia
Neurology
Poor response to 
treatment with IVIG and 
corticosteroids
1 Category III, grade 2C 2nd
No response 
Good tolerance
C 62 F Axonal Guillain-Barré syndrome Neurology
Poor response to 
corticosteroids Possible 
compressive medullary 
syndrome 
1 Category I, grade 1A 1st
No response
Good tolerance
D 44 M Bilateral retrobulbar optic neuromyelitis Neurology
Severe anaphylactic 
reaction to rituximab 1
Category II, 
grade 1B 2nd
Good response
Good tolerance
E 50 M
Progressive 
demyelinating 
polyradiculo-
neuropathy 
Neurology
Good initial response 
to corticosteroids 
Subsequent IVIG 
treatment with poor 
response
1 Category I, grade 1B 2nd
Partial response
Good tolerance
F 68 M Eaton-Lambert syndrome Neurology
No response to 
treatment 1
Category II, 
grade 2C 2nd
Good response
Good tolerance
Complications 
due to catheter 
infection Death
G 40 M
Refractory 
inflammatory 
myopathy
Neurology
Refractory to treatment 
with azathioprine, 
MTX, cyclosporine, 
cyclophosphamide, 
mycophenolate, 
rituximab
1 Category IV, grade 2C 2nd
Good response
Nausea and 
vomiting at start 
of treatment 
Good overall 
tolerance
H 43 F Hypertriglyceridemia Endocrinology and Nutrition
Resolved in the ICU with 
intensive serum therapy, 
absolute diet, and 
insulin
0 Category III, grade 2C
Intention 
to treat
TPE not 
performed
I 72 M
Voltage-gated 
potassium channel 
antibody-associated 
encephalitis
Neurology
Anticonvulsants, 
corticosteroids (no 
response), IVIG (mild 
response)
2 Category III, grade 2C 2nd
Good response
Complication 
due to catheter 
infection 
(resolved)
J 40 M
Voltage-gated 
potassium channel 
antibody-associated 
encephalitis
Neurology IGIV, anticonvulsants, corticosteroids 2
Category III, 
grade 2C 2nd
Good temporary 
response
Good tolerance
K 46 F Waldenström’s macroglobulinemia Hematology
Anaemia due to chronic 
treatment TPE initiated to 
decrease paraproteins 
and initiate rituximab
1 Category I, grade 1C 1st
Good response
Good tolerance 
ASFA, American Society for Apheresis; ICU, Intensive Care Unit; IVIG, Intravenous immunoglobulin; MTX, Methotrexate; TPE, Therapeutic plasma exchange.
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although they recommended IVIG for elderly patients with or without co-
morbidities and for all other patients with comorbidities. Trantafyllou et al.14 
suggested that periodic TPE is safe and effective in controlling the symptoms 
of patients with moderate to severe myasthenia gravis nonresponsive to 
immunosuppressive therapy.
TPE was performed in patient G (40 years, with refractory inflamma-
tory myopathy)3,5 who had been previously treated with azathioprine, 
methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and ritu-
ximab without response. Although this disease is an indication (category 
IV, grade 2C)1 for TPE, this patient benefited from the procedure, with very 
positive results that led to hospital discharge with prednisone as the only 
treatment.
Patients D, E, and F had optic neuromyelitis, polyneuropathy, and Eaton-
Lambert syndrome3, respectively. They had a good initial response to TPE, 
although the final outcomes differed between patients (see Table 2).
Adverse reactions to TPE were observed in only 30% of the patients, 
which is within the range described in the literature (25%-60%)5.
Since TPE may decrease the plasma levels of some drugs5, their phar-
macokinetics should be monitored to ensure the efficacy of concomitant 
treatment.
In conclusion, 80% of the treated patients experienced improvements. 
Although the ASFA guidelines were used to verify the appropriateness 
of the indications for TPE, no direct correlation was observed between the 
grade of recommendation and the response obtained. This study and its 
conclusions may be limited by the small sample size. 
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Contribution to scientific literature
This study provides information on the use of therapeutic plasma 
exchange in the treatment of selected pathologies in a tertiary care hos-
pital. The relevance of this information lies in the variability found in the 
literature on indications, guidelines, results obtained, and interactions 
with standard treatment.
Therapeutic Plasma Exchange is used in the treatment of several au-
toimmune diseases. These diseases have a low incidence. Information 
on this procedure will enhance the provision of more comprehensive 
pharmaceutical care in Hospital Pharmacy Services and contribute to 
obtaining the best possible therapeutic outcomes.
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